MYC and ovarian cancer: In this study, i-BET858 treatment did not elicit consistent and significant c-MYC down-regulation, agreeing with previous data that pointed towards a haematological cancer-specific role of c-MYC as a marker of BETi [52].i-BET858 treatment resulted in a bipartite effect at transcriptomic level, where a core set of differentially expressed genes were shared with i-BET151, with an additional set of approximately 1300 genes regulated uniquely by i-BET858 in our ovarian cancer model.